Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $90.93.

RARE has been the subject of several research analyst reports. Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. HC Wainwright reissued a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Piper Sandler decreased their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. Finally, Morgan Stanley lifted their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $35.40 on Wednesday. Ultragenyx Pharmaceutical has a 1 year low of $29.59 and a 1 year high of $60.37. The firm has a market cap of $3.35 billion, a PE ratio of -5.58 and a beta of 0.34. The company has a 50 day simple moving average of $36.67 and a two-hundred day simple moving average of $42.11.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million for the quarter, compared to the consensus estimate of $145.98 million. During the same quarter in the previous year, the firm earned ($2.03) earnings per share. The company's revenue for the quarter was up 28.0% compared to the same quarter last year. As a group, research analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Activity

In other news, CFO Howard Horn sold 1,785 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the sale, the executive vice president now owns 54,991 shares in the company, valued at approximately $2,358,014.08. This trade represents a 5.16% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 125,405 shares of company stock worth $5,285,169. Corporate insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently bought and sold shares of the company. Northern Trust Corp boosted its stake in Ultragenyx Pharmaceutical by 7.5% in the 1st quarter. Northern Trust Corp now owns 568,389 shares of the biopharmaceutical company's stock worth $20,581,000 after purchasing an additional 39,424 shares in the last quarter. Algert Global LLC boosted its stake in Ultragenyx Pharmaceutical by 57.4% in the 1st quarter. Algert Global LLC now owns 130,320 shares of the biopharmaceutical company's stock worth $4,719,000 after purchasing an additional 47,527 shares in the last quarter. Aberdeen Group plc boosted its stake in Ultragenyx Pharmaceutical by 51.0% in the 1st quarter. Aberdeen Group plc now owns 478,904 shares of the biopharmaceutical company's stock worth $17,341,000 after purchasing an additional 161,779 shares in the last quarter. Oak Ridge Investments LLC boosted its stake in Ultragenyx Pharmaceutical by 2.3% in the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after purchasing an additional 395 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in Ultragenyx Pharmaceutical by 15.3% in the 1st quarter. E Fund Management Co. Ltd. now owns 8,300 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 1,100 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.